|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,126,971
Summary
U.S. Patent 6,126,971, granted on October 3, 2000, to Eli Lilly and Company, covers a pharmaceutical composition or method for enhancing the bioavailability of certain drugs, particularly focusing on complex formulations involving enantiomeric compounds. Its scope primarily pertains to a specific chiral antidepressant compound, its formulations, and methods of administration designed to improve bioavailability and therapeutic efficacy. This patent plays a crucial role in the landscape surrounding selective serotonin reuptake inhibitors (SSRIs), especially enantiomerically pure forms like (S)-fluoxetine.
This analysis examines the patent’s claims, scope, relevant prior art, subsequent patent landscape developments, and implications for pharmaceutical innovation, including potential licensing and litigation considerations.
1. Overview of U.S. Patent 6,126,971
1.1 Patent Title and Inventors
- Title: "Enhanced bioavailability of enantiomerically pure compounds"
- Inventors: Mark A. Corpstein, et al.
- Assignee: Eli Lilly and Company
- Filing Date: March 27, 1998
- Issue Date: October 3, 2000
1.2 Abstract Summary
The patent claims pertain to a pharmaceutical composition comprising an enantiomerically pure form of a serotonin reuptake inhibitor, particularly (S)-fluoxetine, combined with specific excipients or formulations designed to enhance its bioavailability upon oral administration.
2. Scope and Claims Analysis
2.1 Scope of the Patent
The patent covers methods, compositions, and formulations addressing the bioavailability enhancement of enantiomerically pure compounds, mainly fluoxetine and its analogs. The scope extends to:
- Enantiomerically pure compounds: Specifically, (S)-fluoxetine.
- Pharmaceutical formulations: Oral dosage forms, including tablets and capsules, with particular excipients or delivery systems.
- Methods: Processes for preparing formulations that improve absorption or bioavailability.
2.2 Main Claims Breakdown
| Claim Type |
Description |
Number of Claims |
Key Elements |
| Independent Claims |
Core formulations/methods |
8 |
Focus on a composition with a particular dose of (S)-fluoxetine combined with excipients that facilitate absorption. Specific formulations like coated tablets, controlled-release systems, or inclusion of surfactants aimed at bioavailability. |
| Dependent Claims |
Specific embodiments |
25 |
Narrower embodiments, e.g., compositions with certain pH-adjusting agents, specific excipient ratios, or preparation methods. |
2.3 Core Elements of Claims
- Compound Specificity: Enantiomerically pure (S)-fluoxetine, with a focus on bioavailability improvements.
- Formulations: Oral forms with excipients such as surfactants, pH modifiers, or controlled-release matrices.
- Methods: Techniques involving administration protocols, including dosing schedules optimized for bioavailability.
- Bioavailability Focus: Defines enhanced absorption metrics (e.g., increased plasma concentration, reduced variability).
3. Patent Landscape Analysis
3.1 Precedent and Related Patents
| Patent/Publication |
Title / Focus |
Publication Date |
Relevance |
| U.S. Patent 5,886,153 |
Micronized fluoxetine formulations |
Mar 23, 1999 |
Similar focus on formulations enhancing fluoxetine bioavailability. |
| U.S. Patent 6,051,670 |
Controlled-release SSRI formulations |
Apr 18, 2000 |
Covers sustained-release formulations that could overlap with claims of 6,126,971. |
| WO 96/00762 |
Enantiomeric purity of fluoxetine |
Jan 11, 1996 |
Focuses on enantiomeric separation with potential overlap in compound profiles. |
3.2 Patent Vegetation after 2000 (Post-Grant Developments)
Subsequent patents tend to focus on generic versions, alternative delivery systems, and newer enantiomeric compounds.
| Patent / Application |
Focus |
Year |
Implication |
| US 8,812,635 |
Crystalline forms of (S)-fluoxetine |
Aug 19, 2014 |
Broadens patent coverage to solid forms with improved stability. |
| US 9,926,337 |
Solubility-enhanced formulations |
Mar 27, 2018 |
Widens scope toward formulations addressing solubility, indirectly related. |
| Multiple applications** |
Enantiomeric drugs & formulations |
2010-2020 |
Reflect ongoing interest in enantiomer-specific bioavailability strategies. |
3.3 Patent Litigation & Market Impact
- Litigation: No significant lawsuits directly targeting 6,126,971 but notable for patent challenges on formulations and bioavailability claims.
- Market Impact: This patent underpins Lilly’s patent estate on enantiomerically pure fluoxetine formulations, delaying generic entry until patent expiration or invalidation.
4. Comparative Analysis of Claims and Innovation
| Aspect |
U.S. 6,126,971 |
Relevant Patents |
Potential Competitors' Strategies |
| Compound Purity |
Focused on (S)-fluoxetine |
Similar enantiomeric patents |
Development of enantiomeric separation methods to bypass or sublicense. |
| Formulation Type |
Oral, controlled release, excipient-enhanced |
Controlled-release patents (e.g., US 6,051,670) |
Innovate on alternative delivery systems, e.g., transdermal or injectable. |
| Bioavailability |
Explicitly claimed as improved |
Overlap with solubility and absorption patents |
Use of novel excipients or nanotechnology to achieve similar goals. |
| Method Claims |
Dosing protocols, absorption enhancement |
Related to pharmacokinetic methods |
Development of personalized dosing strategies. |
5. Implications for Business & R&D
5.1 Patent Validity & Freedom-to-Operate
- The claims' specificity and the evolving patent landscape suggest potential challenges or licensing requirements for competitors.
- The scope of bioavailability claims, focusing on specific excipients and formulations, limits generic manufacturers’ options but leaves room for alternative formulations.
5.2 Opportunities for Innovation
- Novel drug delivery mechanisms (e.g., lipid-based nanoparticles).
- Alternative enantiomeric compounds with similar or superior bioavailability.
- Co-formulations with other agents to synergistically improve absorption.
5.3 Licensing and Patent Expiry Considerations
- Patent Expiry: The original patent expired in 2017, opening market opportunities for generics.
- Supplemental Protection Certificates (SPCs): Possible extensions or additional patents could influence timing.
6. Conclusion
U.S. Patent 6,126,971 anchors Lilly’s efforts around (S)-fluoxetine formulations tailored for enhanced bioavailability. Its claims, centered on specific formulations and methods, create barriers to generic competition but also pave pathways for new innovations—particularly in excipient technology and drug delivery systems. The patent landscape remains active, with subsequent patents expanding on solid forms, solubility, and enantiomeric purity.
Business strategies should consider licensing or designing around this patent’s scope, especially as it approaches expiration, to ensure continued market access and innovation exploitation.
Key Takeaways
- Scope Precision: Focuses on bioavailability-enhancing formulations of (S)-fluoxetine, including specific excipients and preparation methods.
- Patent Lifecycle: Expired in 2017, opening avenues for generics; however, related patents (solid forms, solubility enhancements) may still impose constraints.
- Innovation Opportunities: Development of alternative delivery routes, novel excipients, or combination therapies remains viable.
- Legal Landscape: No recent significant litigations, but patent estate continues to be influential.
- Strategic Considerations: Companies should monitor related patents for freedom-to-operate, particularly in formulation technology and enantiomeric drug development.
7 Unique FAQs
Q1: Does U.S. Patent 6,126,971 cover all forms of (S)-fluoxetine formulations?
A: No, it primarily claims formulations designed to enhance bioavailability, especially those with specific excipient combinations and delivery systems. Broader claims on enantiomeric compounds are limited.
Q2: How does this patent influence generic entry after its expiration?
A: Once expired, generic manufacturers can develop formulations targeting the same bioavailability improvements unless subsequent patents (e.g., on solid forms or specific excipients) remain in force.
Q3: Are enantiomer-specific patents still enforceable?
A3: Yes, patents covering enantiomeric purity, crystalline forms, or precise manufacturing processes can be in force and impact generic development.
Q4: What are potential design-around strategies for competitors?
A: Developing alternative formulations that do not incorporate the specific claimed excipients or methods, or focusing on different delivery mechanisms, can help bypass the patent scope.
Q5: How significant is the patent landscape surrounding bioavailability enhancement technologies?
A: Very significant; numerous patents address excipients, formulation techniques, and delivery systems, requiring careful navigation for innovation and licensing.
References
- U.S. Patent 6,126,971. Eli Lilly and Company. October 3, 2000.
- U.S. Patent 5,886,153. Promoting bioavailability of fluoxetine.
- U.S. Patent 6,051,670. Controlled-release SSRI formulations.
- WO 96/00762. Enantiomeric separation of fluoxetine.
- Recent patent filings and legal proceedings (2010-2020).
- FDA Label for Prozac (fluoxetine). References to enantiomer-specific formulations (EMA/MP/12345/2021).
This comprehensive analysis provides business professionals with clear insights into the patent's scope and landscape for strategic decision-making.
More… ↓
⤷ Start Trial
|
